Related Experiment Video
Updated: May 13, 2026

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
Published on: May 16, 2021
Opportunities to minimise risk in drug discovery and development
1Director, Biochemical Pharmacology, Roche Palo Alto, m/s R2-101, 3431 Hillview Avenue, Palo Alto, CA 94304, USA. david.swinney@roche.com.
Abstract:
The last decade has seen great advances in defining the molecular components of physiological pathways with the sequencing of the human genome and advances in protein structure analysis. However, these advances have yet to drive an increase in drug discovery productivity. The promise of these advances will begin to be realised as the gap is narrowed for understanding how the composition and structure of biochemical pathways work to provide robust, selective functional responses. This understanding will create new opportunities to discover optimal biochemical pharmacological mechanisms of drug action.
Related Concept Videos
Drug Discovery: Overview
Preclinical Development: Overview
Pharmacogenomics: Identification of New Drug Targets
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Biopharmaceutical Factors Influencing Drug Product Design: Overview
